Scientists report favorable results for inhaled form of insulin

Researchers reported at a European diabetes conference in Munich that Pfizer's Exubera, an inhaled form of insulin for diabetics, proved effective with no more impact on patients' breathing ability than oral drugs taken during a two-year experiment. The results are expected to help Pfizer and its partners in the venture, Aventis and Nektar Therapeutics, receive regulatory approval for the first form of insulin not administered by an injection or an invasive pump.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Santa Clara, CA
Director, Site Quality Management
Minneapolis, MN